COMPASS Pathways (CMPS) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 3[1], 1 Phase 2[2].
Trial NCT05711940[4] evaluates Psilocybin in Treatment Resistant Depression with a target enrollment of 572 participants. Trial NCT05624268[5] evaluates Psilocybin in Treatment Resistant Depression with a target enrollment of 255 participants.
CMPS has 5 Form 4 insider filings recorded at the SEC in the past 30 days[6].